This is a Phase II, non-randomized, open-label, Clinical Trial on the Combination of Carboplatin, Eribulin, and Veliparib in Patients with BRCA-related Cancers.
This is a phase II clinical trial of the combination of carboplatin, eribulin, and Veliparib.